Board Of Directors

Sam Gellman, Ph.D., is the co-founder of Longevity Biotech. He is the Ralph F. Hirschmann Professor of Chemistry and a Vilas Research Professor at the University of Wisconsin - Madison, where he has served on the faculty since 1987. Sam has played a pioneering role in the study of "foldamers," synthetic protein-mimetic oligomers that contain unnatural subunits.

Sam received his A.B from Harvard University, his Ph.D. from Columbia University, and completed his postdoctoral fellowship at the California Institute of Technology. His academic research program has been recognized by many awards. Sam is a member of the US National Academy of Sciences, a fellow of the National Academy of Inventors and a fellow of the American Academy of Arts & Sciences.

Dr. Sanchez has over 20 years of experience in the life sciences industry, and is currently a Senior Advisor at Bain Capital Life Sciences and Norwest Ventures, both investment and venture firms. He also serves on several Board of Directors and Scientific Advisory Boards as well as an Advisor to the NeuroImpact Fund for IASO Ventures. He previously served as Chief Medical Officer of Cerevel Therapeutics Holdings, Inc. (previously Nasdaq: CERE), a biopharmaceutical company, from January 2019 to August 2024 when it was acquired by AbbVie Inc. From November 2007 to January 2019, Dr. Sanchez held various roles of increasing responsibility at Otsuka Pharmaceutical Development & Commercialization, Inc., a privately-held healthcare company, most recently as Senior Vice President, Global Clinical Development beginning in November 2013. From June 2018 to January 2019, Dr. Sanchez concurrently served as Chief Medical Officer of Avanir Pharmaceuticals, Inc., a pharmaceutical company (later acquired by Otsuka America Pharmaceutical, Inc.). Prior to joining the life sciences industry, Dr. Sanchez trained in psychiatry at the Yale School of Medicine where he where he was Chief Resident as well as a fellow and an instructor. Dr. Sanchez was an executive co-chair of the International Society for CNS Drug Development from November 2017 to January 2022, and has also contributed to other academic and charitable organizations such as the Connecticut Mental Health Center Foundation and Yale School of Medicine. He is the recipient of several prestigious awards, including the PharmaVoice 100 for his excellence and innovation in the life sciences, and is also well-published. Dr. Sanchez holds two degrees from Northwestern University, a Bachelor of Arts degree in psychology from the Weinberg College of Arts and Sciences and a medical degree from the Feinberg School of Medicine.

Scott Shandler, Ph.D., MBA, is the co-founder of Longevity Biotech. Prior to founding Longevity, Scott was a venture capitalist at BioAdvance, an early stage fund, where he was responsible for therapeutics, diagnostic and biomarker opportunities. At PolyMedix, Scott assisted with their successful Series A fundraising activities. His work history includes Accenture’s (ACN) Pharmaceutical and Medical Products group, Merck Research Labs (MRK), and Inventa.

Scott received his Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania, an MBA in Health Care Management from The Wharton School, a Certificate of Bioinformatics from Stanford University, along with a B.A. in Computer Science from Brandeis University. He has published in leading peer-reviewed journals, is an inventor on multiple patents and has served as Principal Investigator on federal and private grants.